<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01454336</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-liver-003</org_study_id>
    <nct_id>NCT01454336</nct_id>
  </id_info>
  <brief_title>Transplantation of Autologous Mesenchymal Stem Cell in Decompensate Cirrhotic Patients With Pioglitazone</brief_title>
  <official_title>Phase 1 Trial of Combined Pioglitazone Plus Autologous Bone Marrow Mesenchymal Stem Cell Transplantation in Patients With Compensated Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver cirrhosis (LC) is the final destiny in chronic liver disease. Liver transplantation is
      the only effective therapy available to these patients. However, limited number of donors,
      post surgical complications, immunological rejection, and financial considerations are it`s
      essential problems. The immuomodulatory impact of MSCs in fibrosis was confirmed, and several
      clinical studies have applied MSCs to eliminate the progression of fibrosis. In this research
      the investigators will study the affect of MSCs and Pioglitazone in the process of fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BM Aspiration will be done twice (6 months interval) from the iliac crest according to
      standard procedures under general anesthesia and is collected (200ML) in plastic bags
      containing anti coagulant. After precipitation of red blood cells, mononuclear cells will be
      collected by centrifugation in Ficoll-Paque density gradient. MNCs will be cultured in T150
      flasks. Cells will be expanded in several subcultures.MSCs will be injected (6 months
      interval) via portal vein under sonography monitoring.Each patient will receive 30mg
      Pioglitazone daily for 24 months. After cell therapy, patients are followed up every week for
      6 months, and laboratory data are analyzed for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALT</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of ALT levels during 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AST</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of AST levels after intervention during 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Albumin</measure>
    <time_frame>12 months</time_frame>
    <description>The evaluation of serum albumin levels for 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Fibrosis</measure>
    <time_frame>12 months</time_frame>
    <description>The decrease in grade of liver fibrosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of fibrosis</measure>
    <time_frame>12 months</time_frame>
    <description>Evaluation of fibrosis based on fibroscan and biopsy and scoring</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cirrhotic Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 cirrhotic patients who underwent a combination of cell therapy and chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell injection</intervention_name>
    <description>MSCs introduced into portal vein</description>
    <arm_group_label>Cirrhotic Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 Years cirrhotic patient

          -  Approved cirrhosis by elastografy ,biopsy, sonography

        Exclusion Criteria:

        1 - Portal vein thrombosis 2-Hepatic encephalopathy, score 3&amp;4 3-ALT &amp; AST 3times more than
        normal 4-Serum Cr more than 1/5mg/dL 5-(Anti-HIV +) (Anti-HCV+) (HBS-Ag+) 6-Hepatocel
        carcinoma 7- Primary sclerosing cholangitis (PSC) 8- Esophageal varices grade 4 9-Addiction
        10-Child Score B,C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reza malekzadeh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Director of DDRC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Massoud vosough, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royan regenerative medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2011</study_first_submitted>
  <study_first_submitted_qc>October 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2011</study_first_posted>
  <last_update_submitted>May 10, 2014</last_update_submitted>
  <last_update_submitted_qc>May 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MSCs</keyword>
  <keyword>Pioglitazon</keyword>
  <keyword>fibrosis</keyword>
  <keyword>liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

